SGRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Surgery Partners Inc (SGRY) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive indicators, such as hedge fund buying and improving gross margins, the company's recent financial performance shows declining net income and EPS, and there are no strong proprietary trading signals or significant positive catalysts to justify immediate action. Holding or waiting for more clarity after the upcoming earnings report may be a better approach.
The MACD histogram is positive at 0.119, indicating a potential bullish trend, but it is contracting. RSI is neutral at 52.919, suggesting no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 15.515, with resistance at 15.97 and support at 15.061. Overall, the technical indicators do not provide a strong buy signal.
Analysts remain positive on the managed care sector heading into 2026.
Irenic Capital Management sold over 1 million shares in Q4 2025, reducing its stake. Net income and EPS have both declined significantly YoY, with net income down 28.39% and EPS down 28.00%. The company has no recent congress trading data or strong proprietary trading signals.
In Q3 2025, revenue increased by 6.63% YoY to $821.5 million, but net income dropped by 28.39% YoY to -$22.7 million. EPS also declined by 28.00% YoY to -$0.18. Gross margin improved to 18.97%, up 14.83% YoY, indicating some operational efficiency gains.
Mizuho lowered the price target from $22 to $19 but maintained an Outperform rating. The firm is optimistic about the managed care sector heading into 2026, citing potential margin improvements in commercial, Medicaid, and Medicare segments.
